Loading patent…
AssigneeShijiazhuang Pharma. Group Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
InventorsZhan-qi Niu, Kai Zhao, Wen-juan Liu, Gui-rong Zhou, Chao Liu, Rong-duan Wang, Hong-zhong Yuan, Wen-min Guo, Sui-chao Yan, Min Bai
Estimating the term…
The present invention relates to the inclusion complexes of butylphthalide, which is D, L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-β-cyclodextrin in order to increase the water-solubility of butylphthalide, develop clinical solid or liquid formulations and improve the therapeutic effect of butylphthalide. The inclusion complex, in which the molar ratio of butylphthalide to cyclodextrin or cyclodextrin derivatives is in the range of 1:1-10, can be used to prepare infusion, injection, injectable powder, liquids for oral administration, syrup, tablets, granules, dispersible tablets and others.
A dosage form comprising an inclusion complex of butylphthalide with cyclodextrin derivative which dosage form is an infusion or injection liquid or an injectable powder, wherein said cyclodextrin derivative is selected from the group consisting of hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, dihydroxypropyl-β-cyclodextrin, carboxymethyl-cyclodextrin and sulfonylalkyl-cyclodextrin, and the molar ratio of butylphthalide to the cyclodextrin derivative is 1:1 to 1:10.
Dependencies are inferred from the claim text.